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Abstract: Introduction: The histological diagnosis of prostate cancer is commonly based on morphological patterns. The presence of 
malignant tissue mixed with benign tissue, or the presence of carcinoma that mimics benignity may generate difficulty in the 
diagnostic elucidation. Therefore, the application of immunohistochemistry contributes its diagnostic value. Objectives: To evaluate 
the 34βE12 marker in the detection of adenocarcinoma (ADn), atypical small acinar proliferation (ASAp), regular prostatic tissue 
(RPT) and regular prostatic tissue alternated by atrophy spotlights (RPTa) in transrectal biopsy guided by ultrasonography of patients 
with suspected prostate cancer. Method: Analysis of 34 patients who underwent ultrasound-guided transrectal biopsy with subsequent 
analysis by H&E staining and 34βE12 labeling for elucidation of neoplasms or diseased tissues with doubtful diagnosis. Results: The 
marker 34βE12 showed negativity in 100% of the neoplasms ADn, positivity in 100% of the benign prostatic tissues (RPT and 
RPTa); the patients with ASAp presented positivity (20%) and negativity (80%). The chi-square test (χ²) showed that there is an 
association (χ² = 29.55 and p < 0.0001) between the groups, that is, the 34βE12 marker has a significant value (p < 0.0001) in the 
elucidation of patients with prostatic neoplasia and benign prostatic tissues. Discussion and Conclusion: With the early screening of 
prostate cancer in the modern era, pathologists have become increasingly challenged to diagnose small outbreaks of cancer when 
only a few atypical glands are present in transrectal biopsy-guided ultrasonography. The 34βE12 marker becomes an important tool 
in elucidating diagnoses such as ADn and ASAp. 
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1. Introduction

 
Prostate cancer is a highly prevalent disease and has 
been observed in about three million individuals in the 
US population in the year 2014 [1]. It ranks second 
among malignant neoplasms that affect men worldwide 
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only behind of lung cancer [2]. In 2012, estimates 
revealed approximately 1.1 million new cases, 
constituting 15% of cancers in males [2-4]. In 2017, out 
of every 5 new cases of cancer diagnosed 1 was of 
prostate cancer [5]. 
Prostate specific antigen (PSA), digital rectal 
examination are the most commonly used tools for 
prostate cancer screening. However, transrectal biopsy 
guided by ultrasound remains the gold standard for the 
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final diagnosis. The histological diagnosis of prostate 
cancer is commonly based on morphological patterns. 
However, prostate cancer is a heterogeneous disease 
that can exhibit varying degrees of aggressiveness and 
metastasis patterns; in addition, variable responses to 
treatments. There is a need to go beyond the 
morphological characteristics to stratify patients with 
prostate cancer into more homogeneous groups [6]. 
Histological diagnosis may be challenging because 
there may be malignant tissue mixed with benign tissue, 
or the presence of carcinoma mimicking benignity. 
Therefore, the application of immunohistochemistry 
contributes diagnostic value [7]. 
The differentiation between prostatic 
adenocarcinoma, benign prostatic lesions and the 
process of hyperplasia can be made based on the 
presence or absence of the basal cell layer, considering 
the fact that in the adenocarcinoma there is no cellular 
basal layer. Therefore, the use of immunomarkers such 
as p63 and 34βE12 seems to be useful in differentiating 
these two types of lesions [8-12]. 
Although the immunoreaction may indicate a 
discontinuous or fragmented basal layer, this is not 
indicative of malignancy. Only a few studies indicate 
that there is a positive reaction for neoplastic cells with 
the 34βE12 marker. In contrast, healthy cells react 
continuously to 34βE12, except when they are affected 
by inflammation [13-15]. 
Our objective was to evaluate the 34βE12 marker in 
the detection of adenocarcinoma (ADn), atypical small 
acinar proliferation (ASAp), regular prostatic tissue 
(RPT) and regular prostatic tissue alternated by atrophy 
spotlights (RPTa) in transrectal biopsy guided by 
ultrasonography of patients with suspected prostate 
cancer. 
2. Materials and Methods  
2.1 Ethical Conditions 
The present study was approved by the Research 
Ethics Committee of the Base Hospital Institute of the 
Federal District, Brasília, CAAE: 
90199518.0.0000.8153. 
2.2 Data Collected 
The information was collected through the electronic 
prognosis and anatomopathological reports 
retrospectively. The biopsy indication took into 
account alterations in the PSA level and alterations in 
digital rectal examination. The transrectal image of the 
prostate was obtained with a sectorial transducer for 
subsequent collection of the biopsies, the samples 
obtained by puncture were sextants using 18-gauge 
needle (18-Gauge). These fragments were sent for 
anatomopathological study, being stained by the 
Hematoxylin-Eosin (H&E) technique and diagnosed 
by the same group of pathologists. Subsequently, all 
fragments were stained with the 34βE12 
anti-cytokeratin antibody marker. The 
immunohistochemistry analysis was performed by the 
same group of pathologists and the criteria for 
positivity and negativity were: immunohistochemistry 
with basal layer marking was considered as positive 
and immunohistochemistry without labeling the basal 
layer was considered negative. 
2.3 Patients 
A total of 100 patients underwent ultrasound-guided 
transrectal biopsy with subsequent labeling of the 
34βE12 anti-cytokeratin antibody and were inserted 
into a maintained retrospective database. The variables 
for inclusion of the patients in the study were: (1) 
transrectal biopsy guided by ultrasonography with 
primary analysis of the fragments by the H&E 
technique; (2) subsequent staining of the 34βE12 
anti-cytokeratin antibody; (3) patients with complete 
data in the medical record, such as age, number of 
fragments, sum of Gleason scores. Exclusion criteria 
were: (1) patients who did not undergo transrectal 
biopsy guided by sextant ultrasonography as described 
by Hodge et al. [16] and with less than 12 fragments 
collected for analysis; (2) patients with incomplete data 
to formulate the research. Thus, based on these criteria, 
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34 patients were included for analysis. 
2.4 Statistical Analysis 
The analyzed variables were computed using SPSS 
version 20.0. Clinical and pathological data including 
age, PSA, number of fragments collected, localization 
of diagnosed adenocarcinoma in relation to sites 
collected from ultrasound-guided transrectal biopsy by 
the method of Hodge et al. [16], sum of Gleason score 
on biopsy, percentage of biopsy involvement, marking 
by 34βE12 were analyzed and correlated among the 34 
patients. The analysis of frequencies, mean, standard 
deviation (SD) and range of variation in relation to 
clinicopathological data were described. The 
chi-square test (χ²) with the respective groups and the 
34βE12 marker was based on the 95% confidence 
interval and p < 0.05 as significant. 
3. Results 
Our study analyzed 34 patients who underwent 
ultrasound-guided transrectal biopsy with subsequent 
anatomopathological evaluation by H&E staining. 
These patients presented suspicion of prostate cancer 
or morphological changes characteristic of malignancy 
and, thus, diagnostic complementation by 
immunohistochemistry with the 34βE12 marker was 
required (Table 1). The patients analyzed had a mean 
age of 67.41 years, a standard deviation of 7.44 years, 
and the ages ranged from 55 to 82 years, patients aged 
< 65 years were 10 (29.41%) and ≥ 65 were 24 
(70.58%). In the analysis of the biopsied fragments, we 
showed that the fragments varied from 12 to 23, 
obtained an average of 17.09 fragments, standard 
deviation of 3.08 fragments, patients with 12 fragments 
added 8 (23.52%), 13-19 added 21 (61.76%) and ≥ 20 
added 5 (14.70%). The 34 patients analyzed included 
134 fragments collected for analysis in H&E staining 
that showed 86 (64.17%) fragments with 
adenocarcinoma, 17 (12.68%) with atypical small 
acinar proliferation ranging from 0-5% of biopsy 
involvement, 6 (4.47%) with regular prostatic tissue, 
25 (18.65%) with regular prostatic tissue alternated  
by atrophy spotlights. After the 134 fragments    
were stained with the 34βE12 marker, we noticed some  
 
Table 1  Clinical-pathological characteristics of patients 
Characteristic N (%) 
Age (Mean ± SD*) 67.41 ± 7.44 
< 65/≥ 65 years 10 (29.41)/24 (70.58) 
 Variation: 55-82 years 
Biopsied Fragments (Mean ± SD) 17.09 ± 3.08 
12/13-19/≥ 20 8 (23.52)/21 (61.76)/5 (14.70) 
 Variation: 12-23 fragments 
Diagnosis by the technique H&E** 134 Analyzed Fragments 
ADn/ASAp/RPT/RPTa*** 86 (64.17)/17 (12.68)/6 (4.47)/25 (18.65)  
Diagnosis by technique IHQ**** 134 Analyzed Fragments 
ADn/ASAp/RPT/RPTa 97 (72.38)/3 (2.23)/9 (6.71)/25 (18.65)  
PSA (ng/mL)  
<10/10-20/>20 27 (79.41)/4 (11.76)/3 (8.82) 
IHQ 34βE12  
Positive/negative 37 (27.61)/97 (72.38) 
Gleason Scores on ADn Biopsy  
≤ 6/7/> 7 71 (82.55)/12 (13.95)/3 (3.48) 
*SD—Standard Deviation.  
**H&E—Hematoxylin-Eosin staining.  
***ADn—Adenocarcinoma; ASAp—Atypical Small Acinar Proliferation ranging from 0-5% of biopsy involvement; RPT—Regular 
Prostatic Tissue; RPTa—Regular Prostatic Tissue Alternated by Atrophy Spotlights.  
****Immuno-Histochemistry Anti-Cytokeratin Antibody 34βE12.  
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changes in the pathological report, and 97 (72.38%) 
fragments were confirmed with adenocarcinoma   
(Fig. 1), 3 (2.23%) with atypical small acinar 
proliferation (Fig. 4), 9 (6.71%) with regular prostatic 
tissue (Fig. 2) and 25 (18.65%) with regular prostatic 
tissue alternated by atrophy spotlights (Fig. 3). 
When we analyzed the PSA values, we obtained 27 
(79.41%) patients with PSA < 10 (ng/mL), 4 (11.76%) 
patients with PSA between 10-20 (ng/mL) and 3 
(8.82%) patients with PSA > 20 (ng/mL). When 
analyzing the 134 fragments submitted to staining with 
the 34βE12 marker, we showed that 37 (27.61%) 
fragments showed positivity and 97 (72.38%) of the 
fragments showed negativity for this marker. When 
fragments were diagnosed with adenocarcinoma 
previously by H&E staining, 71 (82.55%) fragments 
obtained ≤ 6 in the sum of Gleason scores, 12 (13.95%) 
fragments obtained 7 in the sum of Gleason scores and 
3 (3.48%) fragments obtained > 7 in the sum of 
Gleason scores. 
After the general stratification of the patients by type 
of diagnosis by H&E staining and subsequent staining 
by the 34βE12 marker, we showed that the marker 
showed negativity in all fragments containing 
adenocarcinoma, showed positivity in all fragments 
that appeared regular prostatic tissues with or without 
being alternated by atrophy spotlights (RPT and 
RPTa), however, when we analyzed patients with 
atypical small acinar proliferation ranging from 0-5% 
of biopsy (ASAp) we found that there were positivity 
(80%) and negativity (20%) (Fig. 5), showing the 
importance of the marker in the diagnostic elucidation 
in ASAp fragments (Table 2). 
When stratifying the fragments diagnosed with 
adenocarcinoma by H&E staining and subsequent 
staining by the 34βE12 marker, we showed that the 
fragments with adenocarcinoma presented in 100% of 
the cases negativity for the 34βE12 marker in different  
 
 
Fig. 1  Some habitual glands, positivity for labeling with 34βE12 (brownish staining), that is, they are delimited by basal cells. 
Other glands were negative for the marker, indicating absence of basal cell delimitation (IHQ-34βE12, 40×). 
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40×                                  100×  
 
400× 
Fig. 2  Usual glands showing positivity for labeling with 34βE12 (brownish staining), that is, they are delimited by basal cells. 
Increasing images of, respectively, 40×, 100× and 400× (IHQ-34βE12). 
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100×                                   400× 
Fig. 3  Atrophic glands with scarce cytoplasm that could be confused with adenocarcinoma in routine staining (H&E). On 
labeling with 34βE12, these glands showed to be positive (brownish staining) or they are delimited by basal cells. Increasing 
images of, respectively, 100× and 400× (IHQ-34βE12).  
 
 
Fig. 4  Multiple glands not evident, negative for labeling with 34βE12. This demonstrates that these glands are not delimited 
by basal cells, something characteristic of the neoplastic alterations in prostatic glands. In the upper part of the image, a 
normal gland, positive for 34βE12 (brownish color) in the basal cells is observed. 
 
fragments with the sum of the Gleason scores and 
different percentages of involvement of the biopsy by 
adenocarcinoma (Table 3). Therefore, it shows that the 
marker has wide utility regardless of the biopsied 
location, Gleason score and percentage of involvement 
of the biopsied fragment. 
When we classified the patients into 3 groups for 
analysis of the chi-square test: neoplastic patients (sum 
of ADn diagnoses) (χ² = 29.55 and p < 0.0001) between 
the groups, i.e., the marker 34βE12 has a significant  
Antibody-Cytokeratin Marker 34βE12 in Prostate Cancer Detection 
  
193 
 
 
(a)                                                (b) 
 
(c) 
Fig. 5  Discrete area containing suspicious, ill-defined, fused glands. Initial diagnosis of atypical small acinar proliferation 
(ASAp) (H&E: 400×). Figs. 5b and 5c. Extensive area containing glands negative for this marker, not delimited by basal cells. 
A partially positive area is shown in Fig. 5c (IHQ-34βE12) (Fig. 5b: 100×; Fig. 5c: 400×). 
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Table 2  Analysis of patients by type of diagnosis with H&E staining and 34βE12 marker. 
  Immunohistochemistry  
Types of Diagnostics* H&E (%) 34βE12  N (%) 
  Negative Positive  
     
ADn  22 (64.70) 22 0 26 (76.47) 
     
ASAp 5 (14.70) 4 1 1 (2.94) 
     
RPTa 6 (17.64) 0 6 5 (14.70) 
     
RPT  1 (2.94) 0 1 2 (5.88) 
     
*ADn—Adenocarcinoma; ASAp—Atypical Small Acinar Proliferation ranging from 0-5% of biopsy involvement; RPT—Regular 
Prostatic Tissue; RPTa—Regular Prostatic Tissue Alternated by Atrophy Spotlights.  
 
Table 3  Analysis of the fragments diagnosed with adenocarcinoma and the labeling pattern of 34βE12. 
Biopsy site of the prostate 
Sum of the Gleason scores 
in the biopsy 
 Percentage of biopsy impairment (%) 34βE12  
 ≤ 6 7 > 7 0-20 > 20-40 > 40-60 > 60-80 Negative Positive 
Base right  16 0 1 11 2 0 4 17 0 
Third middle right 6 0 0 4 0 2 0 6 0 
Apex right  10 0 0 10 0 0 0 10 0 
Base left  16 3 0 16 3 0 0 19 0 
Third middle left 11 3 0 12 2 0 0 14 0 
Apex left 14 6 0 17 3 0 0 20 0 
 
Table 4  Analysis of patients by type of diagnosis and staining by the 34βE12 marker. 
Type of diagnosis by H&E staining All N (%) 34βE12  
  Negative Positive 
Malignant 22 (64.70) 22 0 
ASAp 5 (14.70) 4 1 
Benign Prostatic Tissue* 7 (20.58) 0 7 
(χ² = 29,55 p < 0,0001), *Benign Prostatic Tissue (sum of the regular prostatic tissue and regular prostatic tissue alternated  by 
atrophy spotlights). 
 
Table 5  Analysis of the validity parameters of the diagnosis by H&E having the marker 34βE12 as reference standard. 
     Validity parameters of marker (%)  
  Diagnosis by immunohistochemistry     
Diagnosis by H&E staining ADn  ASAp BPT*     
  34βE12       
  Negative Positive  Sensibility Specificity **PVPR ***PVNR 
ADn   22 0 0 85 100 100 67 
ASAp  4 1 0 100 88 20 100 
*BPT  0 0 7 100 100 100 100 
*BPT—Benign Prostatic Tissue (sum of the regular prostatic tissue and regular prostatic tissue alternated by atrophy spotlights); ** 
PVPR—Predictive Value of a Positive Result; *** PVNR—Predictive Value of a Vegative Result. 
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value (p < 0.0001) to aid the distinction of patients 
previously diagnosed with prostatic neoplasia and 
benign prostatic tissue using the H&E technique. 
However, the 34βE12 marker has 80% of the negativity 
and 20% of positivity for patients previously diagnosed 
with ASAp by the H&E technique (Table 4) (Fig. 5). 
Therefore, it is evident the use of this marker in the aid 
in patients diagnosed with ASAp by H&E to elucidate 
cases undefined by morphology and to avoid 
underdiagnosis of adenocarcinoma. 
When analyzing the validity parameters of the 
diagnosis by H&E staining with the 34βE12 marker, 
we showed that the sensitivity for ADn was 85%,   
100% for ASAp and 100% for BPT (Benign Prostatic 
Tissue—sum of the regular prostatic tissue and usual 
prostatic tissue alternated by atrophy spotlights)  
(Table 5). The specificity for ADn was 100%, 88% for 
ASAp and 100% for BPT. The PVPR for the ADn was 
100%, 20% for the ASAp and 100% for the BPT; the 
PVNR for ADn was 67%, 100% for ASAp and 100% 
for BPT. We evidenced the need for 
immunohistochemistry in the elucidation of doubtful 
diagnoses or not specific for morphology, since 
patients previously classified with ASAp contained 
malignancy characteristics. 
4. Discussion 
Several studies have attempted to find methods of 
elucidating histological diagnosis in prostate cancer 
which in undetermined cases account for 
approximately 1.5-9% of prostate biopsies, therefore, 
the immunohistochemistry application contributes to 
its diagnostic value [17]. 
34βE12 keratin (also referred to as keratin 903-K903) 
is a high molecular weight keratin and was first 
proposed as a basal cell marker. The 34βE12 antibody 
reacts strongly with the total thickness of all stratified 
squamous epithelium (prostate, skin, larynx, esophagus, 
ectocervix and others). In general, positively-labeled 
cells tend to have a more basal location within the 
gland, best represented in the prostate gland. 34βE12 
antibody has not observed reactivity with 
mesenchymal or nerve tissue [18]. 
Wien et al. [19] in a study with 796 biopsies with 
34βE12 staining demonstrated a reduction in the rate of 
doubtful cases from 5.1% to 1.0% and additionally 
offered a means of quality assurance when confirming 
the diagnosis of 61 prostate carcinomas made on the 
basis of samples of biopsy. Abrahams et al. [20] in a 
study with 30 cases, the staining for the 34βE12 
antibody was positive in 26 of the cases with 
involvement classification between < 50% (5 cases), 
50-75% (9 cases), > 75% (10 cases) and > 95% (2 
cases) of the benign glands and in 4 cases (13%) the 
34βE12 failed to stain any tissue, even after repeated 
staining, the 34βE12 antibody in no case stained the 
malignant glands and using the cut of > 75% of 
staining in the benign glands, the sensitivity of 34βE12 
was 40% for benign glands. Several studies have found 
that benign prostatic glands stain positively for the 
34βE12 marker [21, 22]. According to the staining 
pattern, extent and intensity of basal cell markers in the 
benign glands, the 34βE12 marker presented the best 
results, the 34βE12 marker presented the best 
sensitivity and specificity values (95% and 98%, 
respectively). Our study showed that all patients (100%) 
with fragments of benign prostatic glands (regular 
prostatic tissue, regular prostatic tissue alternated by 
atrophy spotlights) presented positivity for the 34βE12 
marker, revealing its high significance (p < 0.0001) in 
the elucidation of benign glands (Tables 2 and 4). 
When analyzing the validity parameters of the H&E 
staining using the 34βE12 marker, we showed a 
sensitivity of 85% for the diagnosis of ADn by H&E 
staining in doubtful cases or not representative by 
biopsy, therefore showing the need for 
immunohistochemistry in cases that do not present a 
totally representative sample by biopsy (Table 5). 
One study evidenced that the 34βE12 marker stained 
negative in all neoplastic areas and stained most (85%) 
of non-neoplastic epithelium [23]. In our study 86 
fragments with diagnosis of ADn by H&E staining 
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were stained with the 34βE12 marker and all showed 
negativity to 34βE12 (Table 1). When stratifying the 86 
(64.17%) fragments of biopsies diagnosed with ADn 
by the sum of the Gleason score (≤ 6, 7, > 7), 
percentage of biopsy involvement (0-20, > 20-40, > 
40-60, > 60-80) and positivity for the 34βE12 marker, 
we showed that regardless of the sum of the Gleason 
scores and the amount of biopsy affected, the 34βE12 
marker was negative in all ADn samples analyzed 
(Table 3). 
Wojno et al. [24] studied 228 cases with 34βE12 
immunostaining and found that the marker was useful 
in establishing, confirming or changing the diagnosis in 
74% of the cases and 64% of the biopsies per needle. 
From these data, they concluded that staining with 
34βE12 is a useful tool in confirming, establishing or 
changing the diagnosis in questionable focus seen in 
the daily practice of pathology [24]. When analyzing 
the patients diagnosed with atypical small acini 
proliferation as an abnormality in the collected 
fragments, we showed that the 34βE12 marker in these 
patients becomes very significant, because of the 5 
(14.70%) patients analyzed, 80% of the cases were 
negative and 20% positive (Fig. 5). Therefore, patients 
with negative staining (80%) were reclassified with 
ADn and the 34βE12 marker was shown to aid in the 
elucidation and differentiation of patients with ASAp 
or ADn (Tables 2 and 4). 
Despite our findings, there are some points that 
could be improved in future studies, including a 
relatively larger population sample. Due to the fact that 
the study was retrospective, it was not possible to add 
other markers for diagnostic comparison and to further 
enrich the statistical analysis. More studies are needed 
to confirm if this would affect the search results. 
5. Conclusions 
Due to the early detection of prostate cancer in the 
modern era, pathologists have become increasingly 
challenged to diagnose small outbreaks of cancer when 
only a few atypical glands are present in needle 
biopsies. The advent of immunohistochemistry has 
become an essential tool in the evaluation of such focus 
to confirm the absence of basal cells.  
Therefore, we conclude that the 34βE12 marker 
becomes an important tool for pathologists in the 
attempt to elucidate diagnoses such as prostatic ADn 
and ASAp. In our study, the 34βE12 marker was very 
significant (p < 0.0001) in the elucidation between 
benign and malignant prostatic tissues, showing a 
strong correlation between 34βE12 marker negativity 
and ADn diagnosis, positivity and diagnosis of benign 
glands.  
Source of Financing 
The author(s) received no financial support for the 
research, authorship, and/or publication of this article. 
Conflict of Interests 
The author(s) declared no potential conflicts of 
interest with respect to the research, authorship, and/or 
publication of this article. 
Acknowledgments 
We would like to thank the staff of the Nucleus of 
Cytopathology and Anatomy-Pathology of the Federal 
District Base Hospital Institute (NUCAP-IHBDF) for 
the help and the assistance during the elaboration of 
this paper. 
References 
[1] Howlader, N., et al., eds. 2017. SEER Cancer Statistics 
Review, 1975-2014. Bethesda: National Cancer Institute. 
[2] Stewart, B. W., and Wild, C. P., eds. 2014. World Cancer 
Report: 2014. Lyon: IARC. 
[3] Ferlay, J., et al., GLOBOCAN. 2012. Cancer Incidence 
and Mortality Worldwide. Lyon, France: IARC, 2013. 
(IARC CancerBase, 11).  
[4] Ferlay, J., et al. 2015. ―Cancer Incidence and Mortality 
Worldwide: Sources, Methods and Major Patterns in 
GLOBOCAN 2012.‖ International Journal of Cancer 
136 (5): 359-86. 
[5] Siegel, R. L., Miller, K. D., and Jemal, A. 2017. ―Cancer 
Statistics, 2017.‖ CA Cancer J Clin. 67: 7–30. 
https://doi.org/10.3322/ caac.21387. 
Antibody-Cytokeratin Marker 34βE12 in Prostate Cancer Detection 
  
197 
[6] Mora, L. B., Buettner, R., Seigne, J., Diaz, J., Ahmad, N., 
Garcia, R., Bowman, T., Falcone, R., Fairclough, R., 
Cantor, A., et al. 2002. ―Constitutive Activation of Stat3 in 
Human Prostate Tumors and Cell Lines: Direct Inhibition 
of Stat3 Signaling Induces Apoptosis of Prostate Cancer 
Cells.‖ Cancer Res. 62 (22): 6659–66. 
[7] Kumaresan, K., Kakkar, N., Verma, A., Mandal, A. K., 
Singh, S. K., and Joshi, K. 2010. ―Diagnostic Utility of 
α-Methylacyl CoA Racemase (P504S) & HMWCK in 
Morphologically Difficult Prostate Cancer.‖ Diagn Pathol 
5: 83. 
[8] Polyak, K., and Weinberg, R. A. 2009. ―Transitions 
between Epithelial and Mesenchymal States: Acquisition 
of Malignant and Stem Cell Traits.‖ Nat Rev Cancer 9: 
265-73. 
[9] Kalantari, M. R., Anvari, K., Jabbari, H., and Varshoee 
Tabrizi, F. 2014. ―p63 Is More Sensitive and Specific than 
34βE12 for Differentiation of Prostate Adenocarcinoma 
from Cancer Mimickers.‖ Iran J Basic Med Sci 17: 
497-501. 
[10] Wang, W., Sun, X., and Epstein, J. I. 2008. ―Parthial 
Atrophy on Prostate Needle Biopsy Cores: A Morphologic 
and Immune Histochemical Study.‖ AM J Surg Pathol 32: 
851-7. 
[11] Brawer, M. K., Peehl, D. M., Stamy, T. A., and Bostwick, 
D. G. 1985. ―Keratin Immune Reactivity in the Being and 
Neoplastic Human Prostate.‖ Cancer Res 45: 3663-7. 
[12] O'Malley, F. P., Grignon, D. J., and Shum, D. T. 1995. 
―Use Fullness of Immune Peroxides Staining with 
High-Molecular-Weight Cytokeratin in the Differential 
Diagnosis of Small-Acinar Lesions of the Prostate  
Gland.‖ Virchows Arch A Patathol Anat Histopathol 417: 
191-6. 
[13] Ramnani, D. M., and Bostwick, D. G. 1999. ―Basal 
Cell-Specific Anti-keratin Antibody 34betaE12: 
Optimizing Its Use in Distinguishing Benign Prostate and 
Cancer.‖ Mod Pathol. 12 (5): 443-4. 
[14] Montironi, R., Bartels, P. H., Hamilton, P. W., and 
Thompson, D. 1996. ―Atypical Adenomatous Hyperplasia 
(Adenosis) of the Prostate: Development of a Bayesian 
Belief Network for Its Distinction from 
Well-Differentiated Adenocarcinoma.‖ Hum Pathol. 27 
(4): 396–407. 
[15] Yang, X. J., Lecksell, K., Gaudin, P., and Epstein, J. I. 
1999. ―Rare Expression of High-Molecular-Weight 
Cytokeratin in Adenocarcinoma of the Prostate Gland: A 
Study of 100 Cases of Metastatic and Locally Advanced 
Prostate Cancer.‖ Am J Surg Pathol. 23 (2): 147–52. 
[16] Hodge, K. K., McNeal, J. E., Terris, M. K., et al. 1989. 
―Random Systematic Versus Directed Ultrasound Guided 
Transrectal Core Biopsies of the Prostate.‖ J Urol 142: 
71-4. 
[17] Iczkowski, K. A., Chen, H. M., Yang, X. J., et al. 2002. 
―Prostate Cancer Diagnosed after Initial Biopsy with 
Atypical Small Acinar Proliferation Suspicious for 
Malignancy Is Similar to Cancer Found on Initial Biopsy.‖ 
Urology 60: 851–4. 
[18] Gown, A. M., and Vogel, A. M. 1984. ―Monoclonal 
Antibodies to Human Intermediate Filament Proteins. II. 
Distribution of Filament Proteins in Normal Human 
Tissues.‖ Am J Pathol 114: 309–21. 
[19] Wien, K. W. 1998. ―Diagnosis of Prostate Carcinoma on 
Biopsy Specimens Improved by Basal-Cell-Specific 
Anti-cytokeratin Antibody (34 beta E12).‖ Sep 110 (17): 
608-11. 
[20] Abrahams, N. A., Ormsby, A. H., and Brainard, J. 2002. 
―Validation of Cytokeratin 5/6 as an Effective Substitute 
for Keratin 903 in the Differentiation of Benign from 
Malignant Glands in Prostate Needle Biopsies.‖ 
Histopathology 41: 35–41. 
[21] Jiang, Z., Wu, C. L., Woda, B. A., et al. 2002. 
―P504S/_-methylacyl-CoA Racemase: A Useful Marker 
for Diagnosis of Small Foci of Prostatic Carcinoma on 
Needle Biopsy.‖ Am J Surg Pathol 26: 1169–74. 
[22] Boran, C., Kandirali, E., Yilmaz, F., Serin, E., and Akyol, 
M. 2011. ―Reliability of the 34βE12, Keratin 5/6, p63, 
bcl-2, and AMACR in the Diagnosis of Prostate 
Carcinoma.‖ Urol Oncol. 29 (6): 614-23. doi: 
10.1016/j.urolonc.2009.11.013. Epub 2010 Mar 2. 
[23] Walter, B., Weiss, T., Hofstädter, F., Gaumann, A., 
Hartmann, A., Rogenhofer, S., Ganzer, R., Wach, S., 
Engehausen, D., Wieland, W. F., and Blana, A. 2013. 
―Utility of Immunohistochemistry Markers in the 
Interpretation of Post High-Intensive Focussed Ultrasound 
Prostate Biopsy Cores.‖ World J Urol. 31 (5): 1129-33. 
doi: 10.1007/s00345-012-0838-9. 
[24] Wojno, K. J., and Epstein, J. I. 1995. ―The Utility of Basal 
Cell-Specific Anticytokeratin Antibody (34 beta E12) in 
the Diagnosis of Prostate Cancer: A Review of 228 Cases.‖ 
Am. J. Surg. Pathol. 19: 251–60. 
 
 
